Grifols gears up for launch of fibrogen therapy after publication of Phase III results Grifols’ fibrinogen therapy BT524 set for EU launch in 2025, and potential US launch next year, after positive AdFIrst Phase III trial results.

Grifols has announced that its fibrinogen concentrate therapy, BT524, is on track for commercial rollout in Europe later this year, with US approval expected by early 2026.

#news #bleedingdisoder #bleeding #fibrinogen #launch

Grifols gears up for launch of fibrogen therapy after publication of Phase III results Grifols’ fibrinogen therapy BT524 set for EU launch in 2025, and potential US launch next year, after positive AdFIrst Phase III trial results.

Grifols has announced that its fibrinogen concentrate therapy, BT524, is on track for commercial rollout in Europe later this year, with US approval expected by early 2026.

#news #bleedingdisoder #bleeding #fibrinogen #launch